Samsara Bio Capital, LLC Cure Vac N.V. Transaction History

Samsara Bio Capital, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 17, 2021	SELL	$56.91 - $127.53 $5.42 Million - $12.2 Million	-95,318 Closed	0 $0
Q4 2020 Feb 17, 2021	SELL	$46.76 - $136.27 $12.9 Million - $37.5 Million	-275,067 Reduced 74.27%	95,318 $7.73 Million
Q3 2020 Nov 16, 2020	BUY	$43.8 - $77.2 $16.2 Million - $28.6 Million	370,385 New	370,385 $17.2 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.